DOCSLIB.ORG

Chemically Induced Or Drug Induced Tinnitus

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Chemically Induced Or Drug Induced Tinnitus International Tinnitus Journal 2, 1-2 (1996) Chemically Induced or Drug Induced Tinnitus Claus-Frenz Claussen, M.D. Department of Neurootology - University E.N. T Clinic, Wiirzburg, Germany or approaching the truth about the clinical accompanying complaints include hearing disorders and F phenomenon of tinnitus from more and more tinnitus. Many patients complain of reduced hearing and possible aspects, it is important in the sense of understanding of speech. Frequent auditory complaints the old Aristotelean systematics of scientific thinking to include a high pitched noise and a sensation of ear choose various and alternating directions for regarding blockage. Diagnosis is elusive, but is eventually the phenomenon. Therefore, today I am also choosing a established. The neurotoxic complications are increased biochemical angle of view. in number and intensity when solvents are multiple in Our model of good and bad hearing, ear noise or tinnitus, number and are released in combination into the is primarily demonstrated in the dimension of physics environment. CTE is a chronic progressive disease. and modern data technology. Hearing is based on the Recently, a male patient, age 58, was seen in consultation transmission of physical sounds from the surrounding for severe tinnitus. A prior diagnosis of CTE had been world by resonance in space to the outer ear; the physical established 26 years ago, secondary to toxic inhalation amplifier of the middle ear; and finally by digital data of trichlorethylene vapors. Tinnitus was reported to have transmission from the cochlea via the hearing pathways been the initial symptom. The patient discovered the to the temporal lobe of the brain. However, the human beneficial effect of acoustical masking by placing the spirit, with all its sensory capacities, does not reside in a noise from a toy train close to the involved ear. It provided technically isolated house nor in a computer, but in a temporary relief from the constant and irritating tinnitus chemically constructed and biologically functioning noise. Today he reports tinnitus control, i.e., relief with a human body. tinnitus masker. The complaint of ear pressure was Many dysfunctions of the central nervous system, eliminated following removal of the patient from the toxic including the symptom of tinnitus can be elicited on a environment. However, the high pitch tinnitus persists. biochemical basis. For example, the toxic effect(s) of Neurotologic evaluation revealed a bilateral sensorineural solvents or the so-called untoward side effects of various hearing loss, primarily cochlear in location; and ab­ drug therapies. normalities in the early and late brain stem potentials. From an ecological as well as as neurotologic standpoint, Vestibular testing with polygraphic electronystagmo­ particularly in the past 30 years, society has become graphy (ENG) and cranio-corpo-graphy (CCG) recor­ increasingly aware of the dangers to human neurosensory dings revealed multiple abnormalities compatible with function(s) secondary to special industrial chemicals central neurotological disturbances. called solvents. A clinical syndrome has been identified, The public and professional communities should become related to this danger, called CHRONIC TOXIC ENCEPHALO­ alert to CTE. Such an awareness will result in its early PATHY (CTE) (Odkvist et aI., 1988). The onset of diagnosis and treatment; and contribute to an increase in symptoms are gradual and increase in intensity and our understanding of environmental hazards to public multiplicity of central nervous system involvement health and concept of tinnitus. Specifically, the concept following an initial and subsequent chronic exposure of and diagnosis of CTE should be expanded to include both the patient to the inhalation from the air of vapors of the the physical and chemical worlds for the evaluation and solvent(s), e.g., Trichlorethylene, Tetrachlorethane, and treatment of the symptom of tinnitus. Hexane (Gasoline), Cyclohexane, Tolluol, Styrene, It is well known among the lay public and medical! Methyl-n-butyl-ketone, Methylchloride, Dichlormethane, audiological professional communities that tinnitus may Trichlorethylene, Perch lor-ethylene, Lindan, etc. be elicited by a toxic drug overdose, e.g., Quinine and The CTE syndrome has been identified in laborers, Aspirin. Many medical treatments elicit a chemically technicians, painters as well as others who work and live induced tinnitus, i.e., iatrogenic. From a medical perspec­ in a polluted environment. The predominant complaints tive, the possibility of a toxic effect of a drug prescribed are disturbances in concentration, memory, cognition, for its pharmacologic and beneficial effect can occur. headache, drowsiness, malaise, and balance complaints Classification of drug pharmaceuticals are primarily described as unsteadiness and dizziness. Significant based on their principle actions. However, it is clear that 1 International Tinnitus Journal Vol. 2, No.1, 1996 Claussen no drug has only a single or specific effect. Chemically, Molindon, Paroxetin, Phenelzin, Protriptilin, Trazodon, extremely unlikely that any drug molecule will bind to Zimelidin, etc. only single species of molecular receptor. The number Several nonsteroidal anti-rheumatic agents may lead to of potential receptors is large in every patient receiving tinnitus as Acetyl-Salicylate, Acemetacine, Benorilate, pharmacological treatment. Even if the chemical structure Benoxaprofen, Carprofen, Chloroquine, Diclofenac, of the drug allows it to bind to only one kind of receptor, Diflunisal, Fenoprofen, Feprazon, Ibuprofen, Indonreta­ the process biochemically controlled by such receptors, cine, Isoxicam, Ketoprofen, Naproxen, D-Pe!licillamin, takes place in many different cell types and is therefore Phenylbutazon, Piroxicam, Proglumetacin, Proquazon, linked to many biochemical functions. The result is that Sulindac, Tolmetin, Zomepirac, etc. both the patient and the physician probably experience The synthetic partially modified glucocorticoide and report more than one drug effect. prednisolone may elicit tinnitus. Tinnitus is a possible Drugs are selective rather than specific in their actions, side effect of local anesthetics such as Bupivacain, because they bind more tightly to one than to a few types Tetracain, Lidocaine, etc. of other receptors. Furthermore, the receptors control Antimalarial agents are potent elicitors of tinnitus, e.g., discrete processes that have a specific effect. It is only Quinine, Quinidine, Chloroquinine, Hydroxychloro­ because of their selectivity that drugs are useful in clinical quine, etc. medicine. However, the benificial effects of drugs must Other therapeutic substances with a potential risk to elicit be routinely evaluated and correlated with their toxic tinnitus include Dihydroergotoxine, Doxylamine, oral effects. Such a correlation is in essence a monitoring sign, contraceptives, Lidoflazine, etc. reflecting the border between the desired beneficial effect Toxic substances long known to physicians to elicit and the deliterious toxic side effect. tinnitus include alcohol, Arsenum, Lead, Caffeine, When studying our phamacologic tool-box we come Marihuana, Nicotine, Mercury, etc. across a broad variety of drugs which eventually elicit This long and incoherent list of tinnitus eliciting drugs is tinnitus. That is an accompaniment of drug overdoses; so diverse that it is difficult to derive or establish one or unusually high drug retention in the body, e.g., due to single paradigm or theory for the specific chemical renal failure. Such drugs include the aminoglycoside interactions within the body as reflected by any and or antibiotics (Streptomycine, Gentamycine, Kanamycine, all of these drugs. However, clinical experience in etc.) medicine has taught that tinnitus is as significant a Other antibiotics include Amphotericine, Chlor­ symptom of human sickness as is pain and dizziness. amphenicol, Minocycline, Polymyxine B, Procain­ Furthermore, it is of interest that several of the above Penicilline, Sulfonamides, Vancomycine, etc. mentioned drugs are recommended for tinnitus treatment: Antineoplastic agents like Bleomycine, Cis-Platinum, Furosemide, Lidocaine, Amitryptiline, Carbamazapine, Carboplatinum, Methotrexate, Nitrogen Mustard, etc. Vinblastin, etc. are known for their possible side effect Scientific investigations attempting to further clarify the in the field of tinnitus. mechanism ciftinnitus production should also consider a The diuretics which may elicit tinnitus as a side effect broad spectrum of facts provided by what is known of include Acetazolamide, Bumetanide, Bendrofluazide, the specific mechanisms of action of the various chemical Clorotalidon, Diapamide, Etcrynic Acid, Furosemide, substances described above, and their biological effects. Hydrochlorthiazide, etc. They are lying in front of us like the "pieces of a puzzle". Another group of drugs which possibly may induce an Until now, the scientists have identified some of the unwanted tinnitus contains cardiac antiarhythmic drugs "pieces of the puzzle", however, they are unable to draw like Celiprolol, Quinidine, Flecainide, Lidocaine, Meto­ the conclusive sketch of the mosaic. These chemical facts prolol, Propranolol, etc. have not yet been placed into the definite puzzle of Psychopharmacological agents which may lead to tinnitus tinnitus. Tinnitus remains a great challenge to the com­ are many and include Amitryptiline, Benzodiazepine, munity of neurotologists and also to modern biomedical Bupropion, Carbamzepine, Diclofensine, Doxepin, sciences. Desipramin, Fluoxetin, Imipramin, Lithium, Melitracen, 2 .
Load more

Recommended publications
  • Table S1: Sensitivity, Specificity, PPV, NPV, and F1 Score of NLP Vs. ICD for Identification of Symptoms for (A) Biome Developm
    Table S1: Sensitivity, specificity, PPV, NPV, and F1 score of NLP vs. ICD for identification of symptoms for (A) BioMe development cohort; (B) BioMe validation cohort; (C) MIMIC-III; (D) 1 year of notes from patients in BioMe calculated using manual chart review. A) Fatigue Nausea and/or vomiting Anxiety Depression NLP (95% ICD (95% CI) P NLP (95% CI) ICD (95% CI) P NLP (95% CI) ICD (95% CI) P NLP (95% CI) ICD (95% CI) P CI) 0.99 (0.93- 0.59 (0.43- <0.00 0.25 (0.12- <0.00 <0.00 0.54 (0.33- Sensitivity 0.99 (0.9 – 1) 0.98 (0.88 -1) 0.3 (0.15-0.5) 0.85 (0.65-96) 0.02 1) 0.73) 1 0.42) 1 1 0.73) 0.57 (0.29- 0.9 (0.68- Specificity 0.89 (0.4-1) 0.75 (0.19-1) 0.68 0.97 (0.77-1) 0.03 0.98 (0.83-1) 0.22 0.81 (0.53-0.9) 0.96 (0.79-1) 0.06 0.82) 0.99) 0.99 (0.92- 0.86 (0.71- 0.94 (0.79- 0.79 (0.59- PPV 0.96 (0.82-1) 0.3 0.95 (0.66-1) 0.02 0.95 (0.66-1) 0.16 0.93 (0.68-1) 0.12 1) 0.95) 0.99) 0.92) 0.13 (0.03- <0.00 0.49 (0.33- <0.00 0.66 (0.48- NPV 0.89 (0.4-1) 0.007 0.94 (0.63-1) 0.34 (0.2-0.51) 0.97 (0.81-1) 0.86 (0.6-0.95) 0.04 0.35) 1 0.65) 1 0.81) <0.00 <0.00 <0.00 F1 Score 0.99 0.83 0.88 0.57 0.95 0.63 0.82 0.79 0.002 1 1 1 Itching Cramp Pain NLP (95% ICD (95% CI) P NLP (95% CI) ICD (95% CI) P NLP (95% CI) ICD (95% CI) P CI) 0.98 (0.86- 0.24 (0.09- <0.00 0.09 (0.01- <0.00 0.52 (0.37- <0.00 Sensitivity 0.98 (0.85-1) 0.99 (0.93-1) 1) 0.45) 1 0.29) 1 0.66) 1 0.89 (0.72- 0.5 (0.37- Specificity 0.96 (0.8-1) 0.98 (0.86-1) 0.68 0.98 (0.88-1) 0.18 0.5 (0-1) 1 0.98) 0.66) 0.88 (0.69- PPV 0.96 (0.8-1) 0.8 (0.54-1) 0.32 0.8 (0.16-1) 0.22 0.99 (0.93-1) 0.98 (0.87-1) NA* 0.97) 0.98 (0.85- 0.57 (0.41- <0.00 0.58 (0.43- <0.00 NPV 0.98 (0.86-1) 0.5 (0-1) 0.02 (0-0.08) NA* 1) 0.72) 1 0.72) 1 <0.00 <0.00 <0.00 F1 Score 0.97 0.56 0.91 0.28 0.99 0.68 1 1 1 *Denotes 95% confidence intervals and P values that could not be calculated due to insufficient cells in 2x2 tables.
    [Show full text]
  • QT Prolongation Due to Roxithromycin
    Postgrad Med J 2000;76:651–654 651 Postgrad Med J: first published as 10.1136/pmj.76.900.651 on 1 October 2000. Downloaded from ADVERSE DRUG REACTION QT prolongation due to roxithromycin A Woywodt, U Grommas, W Buth, W RaZenbeul Roxithromycin and other macrolide antimicro- placement of the apex beat, a prominent third bials are widely used for a broad variety of heart sound, coarse rales over both lung fields infections such as upper respiratory tract infec- and pitting oedema of both ankles. The patient tion and community acquired pneumonia. was taken to an intensive care unit. Acute myo- Prolongation of the QT interval, torsade de cardial infarction was ruled out and frusemide pointes polymorphic ventricular tachycardia, was begun intravenously. An electrocardio- and sudden death are well described but little gram (ECG) on admission showed sinus known adverse reactions common to all rhythm and incomplete left bundle branch macrolides. We report the case of a 72 year old block; QT intervals were normal (QT interval patient with congestive heart failure caused by 380 ms, corrected QT interval according to University of ischaemic heart disease who developed severe Bazett’s formula [QTc] 390 ms). Roxithromy- Hannover Medical prolongation of the QT interval after three days cin (Roussel UCLAF, Romainville, France) School, 30623 of treatment with roxithromycin. 150 mg twice a day was initiated for suspected Hannover, Germany: pneumonia. On the third hospital day, he was Department of Nephrology Case report transferred to a general medical ward. A Woywodt A 72 year old man presented with severe On admission there, the patient was gener- W Buth congestive heart failure.
    [Show full text]
  • Recreational Noise-Induced Hearing Loss
    Hearing loss due to recreational exposure to loud sounds A review World Health Organization Hearing loss due to recreational exposure to loud sounds A review World Health Organization Contributors: Etienne Krug, Maria Alarcos Cieza, Shelly Chadha, Laura Sminkey, Thais Morata, DeWet Swanepoel, Adrian Fuente, Warwick Williams, Joseph Cerquone, Ricardo Martinez, Gretchen Stevens, Margie Peden, Sowmya Rao, Paras Agarwal, Eighmey Zeeck, Anna Bladey, Malachi Arunda, Aileen Ncube. Graphics Credits: INIS Communications WHO Library Cataloguing-in-Publication Data Hearing loss due to recreational exposure to loud sounds: a review. 1.Hearing Loss, Noise-Induced. 2.Music. 3.Noise. 4.Recreation. 5.Noise. Transportation. 6.Adolescent. I.World Health Organization. ISBN 978 92 4 150851 3 (NLM classification: WV 270) © World Health Organization 2015 All rights reserved. Publications of the World Health Organization are available on the WHO website (http://www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for non- commercial distribution – should be addressed to WHO Press through the WHO website (http://www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Ventricular Arrhythmias Associated with Lidoflazine: Side-Effects Observed in a Randomized Trial •Y
    European Heart Journal (1983) 4, 889-893 Ventricular arrhythmias associated with lidoflazine: side-effects observed in a randomized trial •y- S. P. HANLEY AND J. R. HAMPTON Department of Medicine, University Hospital, Queen's Medical Centre, Nottingham NG7 2UH, U.K. Downloaded from https://academic.oup.com/eurheartj/article/4/12/889/503490 by guest on 29 September 2021 KEY WORDS: Angina, exercise testing, lidoflazine, propranolol, ventricular tachycardia. Twenty-four patients received either propranolol, lidoflazine (Clinium), or propranolol/lidoflazine com- binations in a study designed to evaluate the effect of these drugs in angina pectoris. Five patients developed ventricular tachycardia when receiving either lidoflazine or lidoflazine and propranolol in combination; one of these patients died. In addition, one patient died suddenly while being treated with propranolol alone. Lidoflazine therapy was associated with a significant prolongation of the QT interval of the electro- cardiogram. Lidoflazine either alone or in combination with propranolol, appears to induce ventricular tachycardia. Introduction patients already being treated with a beta-blocking, Patients with ischaemic heart disease have an whose symptoms were not adequately controlled; increased risk of death and of developing arrhyth- the second protocol was designed for patients who mias: in any clinical trial of a potential therapeutic were receiving no other treatment other than sub- agent for angina, such events are likely to occur by lingual glyceryl trinitrate. None of thqse patients chance. During a study of lidoflazine we detected was in clinical heart failure. In each of these studies an unacceptable incidence of arrhythmias which exercise tolerance was assessed by treadmill testing led us to discontinue the investigation.
    [Show full text]
  • Can Other People Hear the Noise in My Ears? Not Usually, but Sometimes They Are Able to Hear a (Ertant Type Oftinnitus
    Not at all. Tinnitus is the name for these head noises, and they are very common. Nearly 36 million Americans suffer from this discomfort. Tinnitus mav come and go, or you may be aware of a continuous sound. It can vary in pitch from a low roar to a high squeal or whine, and you may hear it in one or both ears. When the ringing is constant, It can be annoying and distracting. More than seven million people are afflicted so severely that they cannot lead normal lives. Can other people hear the noise in my ears? Not usually, but sometimes they are able to hear a (ertant type oftinnitus. This is called objective tinnitus, and it is caused either by abnormalities in blood vessels around the outside of the ear or by muscle spasms, which may sound like clicks or crackling illside the middle ear. There are many causes for subjective tinnitus, the nOlSC only you can hear. Some causes are not serious (a small plug of wax in the ear canal might cause temporary tinnitus). Tinnitus can also be a symptom of more serious middle ear problems such as infection, a hole in the eardrum, an accumulation of fluid, or stiffening (otosclerosis) of the middle ear bones. Tinnitus may also be caused by allergy, high or 10\V blood pressure (blood circulation problems), OUTER EAR MIDDLE EAR INNER EAR \ a tumor, diabetes, thyroid problems, injury to the head or neck, and a variety of other causes including medications such as anti-inflammatories, antibiotics, sedatives/antidepressants, and aspirin.
    [Show full text]
  • Prohibited Substances List
    Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR). Neither the List nor the EADCM Regulations are in current usage. Both come into effect on 1 January 2010. The current list of FEI prohibited substances remains in effect until 31 December 2009 and can be found at Annex II Vet Regs (11th edition) Changes in this List : Shaded row means that either removed or allowed at certain limits only SUBSTANCE ACTIVITY Banned Substances 1 Acebutolol Beta blocker 2 Acefylline Bronchodilator 3 Acemetacin NSAID 4 Acenocoumarol Anticoagulant 5 Acetanilid Analgesic/anti-pyretic 6 Acetohexamide Pancreatic stimulant 7 Acetominophen (Paracetamol) Analgesic/anti-pyretic 8 Acetophenazine Antipsychotic 9 Acetylmorphine Narcotic 10 Adinazolam Anxiolytic 11 Adiphenine Anti-spasmodic 12 Adrafinil Stimulant 13 Adrenaline Stimulant 14 Adrenochrome Haemostatic 15 Alclofenac NSAID 16 Alcuronium Muscle relaxant 17 Aldosterone Hormone 18 Alfentanil Narcotic 19 Allopurinol Xanthine oxidase inhibitor (anti-hyperuricaemia) 20 Almotriptan 5 HT agonist (anti-migraine) 21 Alphadolone acetate Neurosteriod 22 Alphaprodine Opiod analgesic 23 Alpidem Anxiolytic 24 Alprazolam Anxiolytic 25 Alprenolol Beta blocker 26 Althesin IV anaesthetic 27 Althiazide Diuretic 28 Altrenogest (in males and gelidngs) Oestrus suppression 29 Alverine Antispasmodic 30 Amantadine Dopaminergic 31 Ambenonium Cholinesterase inhibition 32 Ambucetamide Antispasmodic 33 Amethocaine Local anaesthetic 34 Amfepramone Stimulant 35 Amfetaminil Stimulant 36 Amidephrine Vasoconstrictor 37 Amiloride Diuretic 1 Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR).
    [Show full text]
  • Studies on the Possible Mechanisms of Lidoflazine Arrhythmogenicity
    742 lACC Vol 4, No 4 October 1984 742- 7 Studies on the Possible Mechanisms of Lidoflazine Arrhythmogenicity GAD KEREN, MD, DAVID TEPPER, BA, BRENDA BUTLER, BA, WILLIAM MAGUIRE, MD, PHD, HOWARD WILLENS, MD, DENNIS MIURA, MD, PHD , JOHN C. SaMBERG, MD Bronx. New York Lidoftazine is a calcium channel blocking agent that is Dogsalso underwent programmed electrical stimulation effective and safe in the treatment of angina pectoris, while not receiving medications and then after incre­ but has been reported to be associated with sudden death mental doses of lidoftazine administered intravenously. when administered for the treatment of supraventricular Lidoflazinedid not cause spontaneous ventricular tachy­ arrhythmias. Studies were performed in dogs to deter­ cardia and did not lower the threshold of ventricular mine if lidoflazine caused a rise in serum digoxin con­ tachycardia induction. Combined administration of Ii­ centration that could cause arrhythmias or if it was di­ doflazine and digoxin did not facilitate arrhythmia in­ rectly arrhythmogenic. Dogsreceived chronic injections duction. These studies do not support a digoxin-lido­ of digoxin and then digoxin in combination with lido­ f1azine interaction or a direct arrhythmogenic action of ftazine. No increase in digoxin concentration was found. Iidoflazine. Several clinical studies (1-3) have shown the effectiveness Thus. we undertook studies in dogs to test if a digoxin­ and safety of lidoflazine in the control of angina pectoris. lidoflazine interaction exists and causes a rise in serum di­ However, in patients with atrial fibril1ation receiving digi­ goxin levels . Another series of studies used programmed talis therapy and being treated with Iidoflazine to convert electrical stimulation techniques to determine whether suc­ the supraventricular arrhythmia.
    [Show full text]
  • Material Safety Data Sheet
    MATERIAL SAFETY DATA SHEET Prepared to U.S. OSHA, CMA, ANSI and Canadian WHMIS Standards PART I What is the material and what do I need to know in an emergency? 1. PRODUCT IDENTIFICATION TRADE NAME (AS LABELED) : MERCURY CHEMICAL NAME/CLASS : Mercury; Element SYNONYMS: Colloidal Mercury, Quick Silver; Liquid Silver; NCI-C60399; Hydrargyrum PRODUCT USE : Variety of industrial, analytical, and research applications. SUPPLIER/MANUFACTURER'S NAME : COMPANY ADDRESS : DFG MERCURY CORP 909 pitner Evanston Ill 60202 EMERGENCY PHONE : 1 800 424 9300 BUSINESS PHONE : 1 847 869 7800 DATE OF PREPARATION : May 20, 1997 DATE OF REVISION : October 7, 2013 2. COMPOSITION and INFORMATION ON INGREDIENTS CHEMICAL NAME CAS # %w/w EXPOSURE LIMITS IN AIR ACGIH-TLV OSHA-PEL OTHER TWA STEL TWA STEL IDLH mg/m 3 mg/m 3 mg/m 3 mg/m 3 mg/m 3 mg/m 3 Mercury 7439-97-6 100 0.025, (skin) NE Mercury 0.1 (ceiling) 10 NIOSH REL: Exposure limits are A4 (Not Vapor: 0.5, STEL = 0.1 (ceiling, for Mercury, Classifiable Skin; Non-alkyl Mercury skin) Inorganic as a Human (Vacated Compounds: 0.1 DFG MAKs: Compounds Carcinogen) 1989 PEL) Ceiling, skin TWA = 0.1 (Vacated 1989 PEAK = 10 •MAK 30 PEL) min., momentary value Carcinogen: EPA-D; IARC-3, TLV-A4 NE = Not Established. See Section 16 for Definitions of Terms Used. NOTE: ALL WHMIS required information is included in appropriate sections based on the ANSI Z400.1-1998 format. This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all the information required by the CPR.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Hearing Loss
    Integrated care for older people (ICOPE) Guidelines on community-level interventions to manage declines in intrinsic capacity Evidence profile: hearing loss Scoping question: Does case finding and provision of hearing aids or assistive listening devices produce any benefit or harm for older people 60 years of age and over with hearing loss? The full ICOPE guidelines and complete set of evidence profiles are available at who.int/ageing/publications/guidelines-icope Painting: “Wet in Wet” by Gusta van der Meer. At 75 years of age, Gusta has an artistic style that is fresh, distinctive and vibrant. A long-time lover of art, she finds that dementia is no barrier to her artistic expression. Appreciated not just for her art but also for the support and encouragement she gives to other artists with dementia, Gusta participates in a weekly art class. Copyright by Gusta van der Meer. All rights reserved Evidence profile: hearing loss Contents Background ....................................................................................................................................................................................................... 1 Part 1: Evidence review .................................................................................................................................................................................... 2 Scoping question in PICO format (population, intervention, comparison, outcome) ............................................................................................. 2 Search strategy
    [Show full text]
  • Drug Induced Long QT Syndromes: Lethal Reactions to ‘Benign Drugs’ - May/2005 Dr
    Drug Induced Long QT Syndromes: Lethal Reactions to ‘Benign Drugs’ - May/2005 Dr. R.G.Williams Long QT syndrome (LQTS) ¾ A disorder of myocardial repolarization characterized by a prolonged QT interval on ECG. ¾ ↑ risk of a characteristic life-threatening cardiac arrhythmia, known as torsade de pointes (TdP) VT. ¾ Drug induced usually with bradycardia ¾ Short-long cycles 2o VPBs ¾ Present with: z Palpitations z Syncope z Seizures z Sudden cardiac death (SCD) ¾ Congenital – 2 phenotypes z Romano – Ward: more common, purely cardiac • Autosomal dominant z Jervell + Lange-Nielsen: sensorineural deafness • Autosomal recessive ¾ At least 7 genes described LQTS 1 - 7 ¾ Affect Na and K channels ¾ Acquired LQTS may be a ‘forme fruste’ Acquired LQTS ¾ Commonest causes z Medications z Electrolyte disorders ¾ Others z Structural heart disease z Stroke + brain injury z HIV z Eating disorders May, 2005 1 Talk edited into handout by RAS Long QT of Hypocalcemia May, 2005 2 Talk edited into handout by RAS Drug Induced LQTS ¾ First recognized in 1920s – quinidine syncope ¾ Monitoring identified typical sequences in TdP in 1960s ¾ In the past decade, the single most common cause of the withdrawal or restriction of the use of drugs that have already been marketed has been the prolongation of the QT interval associated with polymorphic ventricular tachycardia, or torsade de pointes. ¾ Nine structurally unrelated drugs removed or severely restricted due to QT ↑ + TdP. Risk Factors for TdP ¾ Drug regimen: z Not usually an idiosyncratic event z ↑drug dose or
    [Show full text]